JAK1 and acute lymphoblastic leukemia: The proliferation of JAK1S646F-transformed Ba/F3 cells was inhibited by ruxolitinib and also a PDX model of JAK1 mutant B-ALL showed sensitivity to ruxolitinib [56,85,87].